Brief: Theseus Pharmaceuticals Announces Business And Program Highlights And Reports Third Quarter 2021 Financial Results
15/11/2021 12:17
Nov 15 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS AND PROGRAM
HIGHLIGHTS AND REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS
* Q3 LOSS PER SHARE $5.16
* INITIATION OF PHASE 1/2 CLINICAL TRIAL FOR THE-630
EXPECTED
BETWEEN LATE Q4 2021 AND MID-Q1 2022
* EXPECTS CASH, CASH EQUIVALENTS, INCLUDING PROCEEDS FROM
IPO, TO
FUND OPERATIONS AND CAPITAL EXPENDITURES INTO H2 2024
Source text for Eikon: ID:nPnWnB2ca
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7